Recursion Pharmaceuticals stock analysis: RXRX nears its two-year low as revenue drops 60.1% TTM and cash burn continues despite a strong balance sheet.
@2026 – All Right Reserved.
Tag:
Biotechnology
-
-
Generate Biomedicines, Inc. stock analysis: GENB hits a 2-year high on thin revenue, deep losses, and a still-unrated valuation signal.
-
BiotechnologyUS Stocks
Legend Biotech’s 93/100 Growth Score Collides With a Stock Near Two-Year Lows
Legend Biotech Corporation stock analysis: 51.9% TTM revenue growth, near two-year lows, Hold signal on thin margins and no usable P/E.
-
BiotechnologyUS Stocks
Parabilis Medicines Just Hit a Two-Year High – But the Model Can’t Issue a Verdict Yet
Parabilis Medicines, Inc. stock analysis: shares hit a two-year high, but no P/E or P/B means the model can’t issue a Buy/Hold/Sell call.
-
BiotechnologyUS Stocks
Beam Therapeutics’ Growth Is Explosive, but the Stock Already Reflects Plenty of Hope
Beam Therapeutics Inc. stock analysis: insights on fundamentals, biotech trends, and growth potential for informed healthcare sector investing.
-
BiotechnologyUS Stocks
The Precision Medicine Play Getting Punished: Can Caris Life Sciences Justify Its $4.7 Billion Valuation?
Caris Life Sciences, Inc. stock analysis: explore fundamentals, financial metrics, and investment potential in precision medicine diagnostics.